PFE PFIZER INC — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$27.5

Period return

+0.40 (+1.48%)

Volume

24.0M

2026-10-06O $27.48 H $27.71 L $27.2 C $27.5MA5 $27.87MA20 $27.94MA60 $27MA120 $26.33

6M · 127 barsYahoo Finance · USD2026-04-07 → 2026-10-06

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 06. 28.Medium3 months ago
Q2 2026 earnings
EPS -0.04 · 매출 150.3억. 세부 수치와 가이던스는 원문에서 확인하세요.
2026. 05. 15.High5 months ago
13F 기관 보유 변화 — Point72 Asset Management, L.P.
신규 편입 · 포트폴리오 비중 0.22%
2026. 05. 15.High5 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.01%
2026. 03. 29.Medium6 months ago
Q1 2026 earnings
EPS 0.47 · 매출 144.5억. 세부 수치와 가이던스는 원문에서 확인하세요.
2025. 12. 31.Medium9 months ago
Q4 2025 earnings
매출 175.6억. 세부 수치와 가이던스는 원문에서 확인하세요.
2025. 09. 28.Mediumlast year
Q3 2025 earnings
EPS 0.62 · 매출 166.5억. 세부 수치와 가이던스는 원문에서 확인하세요.
2025. 06. 29.Mediumlast year
Q2 2025 earnings
EPS 0.51 · 매출 146.5억. 세부 수치와 가이던스는 원문에서 확인하세요.
2025. 03. 30.Medium2 years ago
Q1 2025 earnings
EPS 0.52 · 매출 137.2억. 세부 수치와 가이던스는 원문에서 확인하세요.
2024. 12. 31.Medium2 years ago
Q4 2024 earnings
매출 177.6억. 세부 수치와 가이던스는 원문에서 확인하세요.
2024. 09. 29.Medium2 years ago
Q3 2024 earnings
EPS 0.78 · 매출 177억. 세부 수치와 가이던스는 원문에서 확인하세요.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
FY2026 Q2	2026. 06. 28.	Time TBD	—	$-0.04	—	—	$15.03B	Reported
FY2026 Q1	2026. 03. 29.	Time TBD	—	$0.47	—	—	$14.45B	Reported
FY2025 Q4	2025. 12. 31.	Time TBD	—	—	—	—	$17.56B	Reported
FY2025 Q3	2025. 09. 28.	Time TBD	—	$0.62	—	—	$16.65B	Reported

Research actions

Consensus PT $28.91 · 26 analysts

Research tab →

No research actions to show.

Key stats

As of FY2026Q2 · Source: SEC/DART + price data

Market cap$156.74B

Shares out.5,700M

PER20.22x

EPS (TTM)$1.36

PBR1.84x

BPS$14.95

Dividend/share—

Dividend yield—

ConsensusBuy

Price target$28.91+5.1%

Target range$25.00 ~ $35.75· 26 analysts

Last earnings vs est.Beat +12.9%

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	4,365,063	$122.57M	0.22%	—	New position
2	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	3,305,692	$82.31M	0.13%	—	New position
3	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	2,068,108	$51.5M	0.08%	—	New position
4	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	212,100	$5.96M	0.01%	—	New position

Company info

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Sector: Healthcare
Industry: Drug Manufacturers - General
HQ: New York, NY, United States
Fiscal year end: —
Employees: 75,000
IPO date: —

View details →

Top news

Stored first · Google News · Yahoo Finance (English)

Quarter

Date

Time

EPS est.

EPS actual

Surprise

Rev. est.

Rev. actual

Status

FY2026 Q2

2026. 06. 28.

Time TBD

—

$-0.04

—

$15.03B

Reported

FY2026 Q1

2026. 03. 29.

Time TBD

—

$0.47

—

$14.45B

Reported

FY2025 Q4

2025. 12. 31.

Time TBD

—

$17.56B

Reported

FY2025 Q3

2025. 09. 28.

Time TBD

—

$0.62

—

$16.65B

Reported

Institution

Mandate

Value

Weight

Change

Position

Point72 Asset Management, L.P.

4,365,063

$122.57M

0.22%

—

New position

Point72 Asset Management, L.P.

3,305,692

$82.31M

0.13%

—

New position

TWO SIGMA INVESTMENTS, LP

2,068,108

$51.5M

0.08%

—

New position

TWO SIGMA INVESTMENTS, LP

212,100

$5.96M

0.01%

—

New position